Study Details
Grekin Skin Institute is enrolling adults for a Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concept trial of ADX-914 for the treatment of severe Alopecia Areata study.
The purpose is to evaluate how effective injections of the investigational drug called ADX-914 is on reducing hair loss in patients with severe alopecia areata. The study consists of receiving an injection under the skin of either the investigational product ADX-914 or placebo every 2 weeks over a 24-week period. You will be randomly assigned to receive the study drug or placebo. You have 3:1 chance (75%) of receiving the investigational product.
There is no cost to participate, and insurance is not required. Qualified participants will be under the supervision of a board-certified dermatologist and receive up to $1,700 compensation for time and travel.
Compensation: $100 per visit, up to $1,700
Duration: 36 weeks
Visits: up to 17
Sex: Male or Female